Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 10 of 11« First...7891011

Oral OTEZLA (Apremilast) Demonstrated Significant Improvement versus Placebo in Trial of Patients with Moderate Plaque Psoriasis Who Were Naïve to Systemic and Biologic Therapy

Encouraging results were reported from UNVEIL, the first trial of patients with moderate plaque psoriasis who were naïve to systemic and biologic therapy.

Read More »

Seattle Genetics to resume trials as FDA lifts clinical hold

Seattle Genetics Inc. said the U.S. Food and Drug Administration lifted a clinical hold on several early-stage studies testing its experimental cancer drug.

Read More »

Latest Dupixent eczema drug tests positive

Sanofi and Regeneron said results from a one-year test of Dupixent aimed at adults with eczema or moderate-to-severe atopic dermatitis had been positive.

Read More »

J&J wins trial in talc product liability lawsuits

A state court jury in Missouri returned a verdict in J&J’s favor in the latest trial arising out of lawsuits alleging its talc-based products can increase ovarian cancer risk.

Read More »

Britain detects bird flu on premises in eastern England

Britain said it had detected bird flu on premises in eastern England during routine checks carried out following the confirmation of the virus at a nearby farm.

Read More »

Current Realities of the Audience Economy, from a Programmatic Perspective

Healthcare marketers have this grand vision of reaching the right patient/caregiver/healthcare professional (HCP) with the right message, at the right time, in the right context.

Read More »

Following Up on Bristol-Myers Squibb’s Restructuring Plans, Company Makes Move to Shift 1,250 Workers Out of Hopewell Township Site

In October, Bristol-Myers Squibb announced a reorganization plan of its research and development group. Part of that restructuring will include the closure of two sites in Hopewell Township by 2020 – a move that could displace up to 1,250 employees.

Read More »

Guselkumab Outperforms Humira In Study

Study data showed patients treated with guselkumab experienced significantly greater improvements compared with the anti-TNF-alpha treatment Humira.

Read More »

Chi-Med Shows Off Phase III Cancer Drug Data

Chi-Med’s fruquintinib met all main endpoints in a Phase III trial as a third-line treatment in patients with locally advanced or metastatic colorectal cancer.

Read More »

Sanofi Pasteur Inks $645 Million RSV Deal With AstraZeneca’s MedImmune

Paris-based Sanofi Pasteur announced that it had inked a development agreement with MedImmune, the research-and-development art of AstraZeneca.

Read More »

Analyze the Pill Burden Domino Effect on Healthcare Known as Polypharmacy

Understand the meaning and implications of polypharmacy and the issues it causes for patient adherence; Discover policies, technologies and procedures that can eliminate or reduce the effects of polypharmacy ensuring quality outcomes; Highlight issues Pharmacist Partners, as an organization, has remedied and the technology they utilize to decrease overuse or underuse of medication

Read More »

Governors met on Obamacare replacement plan with Pence

Ten state governors seeking to avoid millions of dollars in federal healthcare cuts under Republican plans to replace Obamacare pressed their case in a meeting with Vice President Mike Pence, according to two people briefed on the talks.

Read More »

Herbal medications risky in heart disease

Herbal medications offer few benefits and many risks for people with heart disease, according to a recent review.

Read More »

PTC abandons cystic fibrosis drug after trial failure

PTC Therapeutics Inc. said it would stop developing its cystic fibrosis drug after it failed to meet the main goal of a late-stage study.

Read More »

Mutual Recognition promises new framework for pharmaceutical inspections for United States and European Union

The United States and the European Union (EU) completed an exchange of letters to amend the Pharmaceutical Annex to the 1998 U.S.-EU Mutual Recognition Agreement. Under this agreement, U.S. and EU regulators will be able to utilize each other’s good manufacturing practice inspections of pharmaceutical manufacturing facilities.

Read More »

Backed by Amazon and Big Names Like Bristol-Myers Squibb, Celgene and Merck & Co., Bay Area’s GRAIL Banks $900 Million

Grail Inc., a company focused on using diagnostics to develop early-stage cancer detection, bagged $900 million in Series B financing.

Read More »

10 Biotechs With an Orphan Drug in Late-Stage Pipeline

Citing a recent evaluation of the orphan drug market by Evaluate, Endpoints picked 10 orphan drug candidates that could, if approved, become blockbusters, or near blockbusters, by 2022.

Read More »

Juno Finally Drops Problem CAR-T Drug That Caused Deaths

Juno pulled the plug on its once-promising lead CAR-T cancer treatment JCAR015.

Read More »

Roche drug cocktail cuts breast cancer deaths

Roche’s bid to shield its lucrative oncology franchise from generics got a lift from a trial showing a new drug cocktail kept breast cancer patients alive longer.

Read More »

South Korea fines Novartis over kickbacks, suspends sales of some drugs

South Korea said it has fined Swiss drugmaker Novartis 200 million won ($174,937) and temporarily banned sales of some of its drugs for paying kickbacks to doctors in exchange for recommending the company’s drugs.

Read More »

Page 10 of 11« First...7891011

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2018 Focus: Top 10 Pipelines, Focused Value in Pharma, Agenda 2018 and MAHF!


Ad Right Bottom

Main Navigation